A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders

Trial Profile

A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GALLIUM
  • Sponsors Chugai; Nippon Shinyaku; Roche
  • Most Recent Events

    • 16 Nov 2017 Results presented in a Genentech Media Release.
    • 16 Nov 2017 According to a Genentech media release, based on the data from this study, the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV).
    • 01 Nov 2017 According to a Genentech media release, data from the study will be presented at the American Society of Hematology (ASH) 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top